Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eletriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B known ✓ | P28222 | 7/20 | 0.98 |
| ▸ | HTR1D known ✓ | P28221 | 6/20 | 0.65 |
| ▸ | HTR1F known ✓ | P30939 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 3/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.98 |
| ▸ | HTR6 | P50406 | 15/20 | 0.66 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eletriptan SCHEMBL4431798 | 1.00 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL29984875 | 1.00 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL4233264 | 1.00 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL3713443 | 1.00 | HTR1B (0.98) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL2146547 | 0.99 | HTR1B (0.96) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL798473 | 0.99 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL29414096 | 0.99 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL26719 | 0.99 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL1556539 | 0.99 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 | |
| Eletriptan SCHEMBL10083479 | 0.99 | HTR1B (1.00) | HTR1BHTR1ACHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605362-B2 | — | — | 2026-04-21 | — | — | US | claimed |
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20230346746-A1 | ELETRIPTAN HYDROBROMIDE FOR TREATMENT OF SPINAL CORD INJURY AND IMPROVEMENT OF LOCOMOTOR FUNCTION | FUNDAÇÃO GIMM – GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE (PT) | 2023-11-02 | — | — | US | claimed |
| EP-4093395-B1 | ELETRIPTAN HYDROBROMIDE FOR TREATMENT OF SPINAL CORD INJURY AND IMPROVEMENT OF LOCOMOTOR FUNCTION | TECHNOPHAGE INVESTIG E DESENVOLVIMENTO EM BIOTECNOLOGIA SA (PT) | 2023-10-25 | — | — | EP | claimed |
| CN-116036051-A | Eletriptan hydrobromide oral film-dissolving agent | 湖北广济医药科技有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-11623052-B2 | Dry powder drug delivery system and methods | MANNKIND CORPORATION (US) | 2023-04-11 | — | — | US | claimed |
| EP-4093395-A1 | ELETRIPTAN HYDROBROMIDE FOR TREATMENT OF SPINAL CORD INJURY AND IMPROVEMENT OF LOCOMOTOR FUNCTION | Technophage, Investigação e Desenvolvimento em Biotecnologia, SA (PT) | 2022-11-30 | — | — | EP | claimed |
| EP-4082546-A1 | METHODS OF TREATMENT WITH CYP3A4 SUBSTRATE DRUGS | Bow River LLC (US) | 2022-11-02 | — | — | EP | claimed |
| EP-1135381-B1 | ELETRIPTAN HYDROBROMIDE MONOHYDRATE | PFIZER LTD (GB) | 2004-08-11 | — | — | EP | claimed |
| US-20040131661-A1 | Process for making orally consumable dosage forms | PFIZER INC. | 2004-07-08 | — | — | US | claimed |
| WO-2004012720-A1 | PROCESS FOR MAKING ORALLY CONSUMABLE DOSAGE FORMS | PFIZER LIMITED (GB) | 2004-02-12 | — | — | WO | claimed |
| EP-1365748-A2 | PARTICULATE COMPOSITION OF ELETRIPTAN SHOWING A SIGMOIDAL PATTERN OF CONTROLLED RELEASE | Pfizer Limited (GB) | 2003-12-03 | — | — | EP | claimed |
| WO-2002009675-A9 | PARTICULATE COMPOSITION OF ELETRIPTAN SHOWING A SIGMOIDAL PATTERN OF CONTROLLED RELEASE | PFIZER LTD (GB) | 2003-09-18 | — | — | WO | claimed |
| US-20020034545-A1 | Particulate composition of eletriptan | PFIZER, INC. | 2002-03-21 | — | — | US | claimed |
| WO-2002009675-A1 | PARTICULATE COMPOSITION OF ELETRIPTAN SHOWING A SIGMOIDAL PATTERN OF CONTROLLED RELEASE | PFIZER LIMITED (GB) | 2002-02-07 | — | — | WO | claimed |
| US-20020013358-A1 | For therapy of migraine, recurrent migraine, hypertension, depression, emesis, anxiety, an eating disorder, obesity, drug abuse, cluster headache, pain, chronic paroxysmal hemicrania and headache | PFIZER INC. | 2002-01-31 | — | — | US | claimed |
| EP-1135381-A1 | ELETRIPTAN HYDROBROMIDE MONOHYDRATE | Pfizer Limited (GB) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032589-A1 | ELETRIPTAN HYDROBROMIDE MONOHYDRATE | PFIZER LIMITED (GB) | 2000-06-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605362-B2 | — | BDNF, DCX, ELAVL1 | HTR1B 243/4885HTR1D 78/4885HTR1F 197/4885 |
| US-20020013358-A1 | For therapy of migraine, recurrent migraine, hypertension, depression, emesis, anxiety, an eating disorder, obesity, drug abuse, cluster headache, pain, chronic paroxysmal hemicrania and headache | HTR2B, HTR4, HTR1A | HTR1B 5/4885HTR1D 13/4885HTR1F 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.